Nanomaterials in FDA regulated products: moving forward with science-based risk assessment Paul C. Howard, Ph.D. Director, Office of Scientific Coordination, Acting Director, NCTR/ORA Nanotechnology Core Facility (NanoCore), National Center for Toxicological Research, U.S. Food & Drug Administration, Jefferson AR USA
28
Embed
Nanomaterials in FDA regulated products: moving forward with
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Nanomaterials in FDA regulated products: moving forward with science-based risk assessment
Paul C. Howard, Ph.D.
Director, Office of Scientific Coordination,Acting Director, NCTR/ORA Nanotechnology
Core Facility (NanoCore),National Center for Toxicological Research,
U.S. Food & Drug Administration, Jefferson AR USA
Disclaimer:The presenter, and not the FDA, is responsible for the accuracy of this presentation.
The views, opinions, and/or conclusions are those of the presenter only, and should not be considered as current or future official position or policy of the U.S. Food & Drug Administration (FDA), or any component of the U.S. Government. Any mention of commercial organizations or trade names is not intended as endorsement.
FDA Mission
- Protect public health by ensuring safety, efficacy and security of human and animal drugs, biological products, medical devices, food supply, cosmetics, and products that emit radiation.- Advance public health by speeding innovations for more effective, safe and affordable medicines and food.- Provide public with accurate, science-based information. Underlined for emphasis only;
related to food or food safety
Products Regulated by FDA
Foods• All interstate domestic
and imported; includingproduce, fish, shellfish,shell eggs, milk; exceptmeat and poultry.
• Bottled water.• Wine (<7% alcohol).• Infant formula
Food Additives• Colors• Food containers
Cosmetics
Dietary SupplementsAnimal FeedsPharmaceuticals
• Human (safety, efficacy)• Animal (safety, efficacy)
Medical DevicesRadiation Producing DevicesVaccinesBlood ProductsTissuesSterilantsTobacco
Center for Biologics and Experimental Research, CBER
Center for Drugs and Experimental Research, CDER
Center for Devices and Radiological
Health, CDRH
Center for Veterinary
Medicine, CVM
Center for Food Safety and Applied Nutrition, CFSAN
National Center for Toxicological
Research, NCTR
Center for Drugs and Experimental Research, CDER
FDA
Office of the Commissioner
Center for Tobacco Regulation, CTR
Office of Regulatory Affairs
NCTR Mission
FDA’s National Center for Toxicological Research(NCTR, Jefferson, AR)
- Conduct peer-reviewed toxicological research in support of FDA mission for science-based regulatory decisions to improve health of US public:- Understand critical biological events in toxicity;- Develop and characterize methods and incorporate new technologies to improve assessment of human exposure, susceptibility and risk;- Increase understanding of interaction between genetics, metabolism and nutrition. Underlined for emphasis only;
related to food or food safety
Nanotechnology = enabling the synthesis of materials with unique and controllable properties; nanotechnology-based materials ≈ 1~100 nm;
Nanomaterials are, or are reportedly, being included into many FDA-regulated products.
“there are many challenges associated with each of these modules that feed into any risk assessment model; these challenges are exacerbated when studying nanomaterials”
What is the behavior of nanomaterials in the traditional in vitro and in vivotoxicity assays?
If a nanomaterial is toxic, will it be detected in the current ‘battery’ used by regulatory agencies (false negative; false positive)?
Will nanoparticle and nanomaterial behavior interfere with toxicity assays?
Toxicity
Example: “Method for Analysis of Nanoparticle Hemolytic Properties In Vitro”, Dobrovolskaia et al., NanoLetters 8, 2180-2187, 2008
“… 50 nm nanoparticles, absord hemoglobin .. and the adsorbed hemoglobin precipitates with the particles upon centrifugation, yielding a false negative result…”
“The most common mechanism of interference is due to the nanoparticle absorbance at or close to the assay wavelength (540 nm).”
FDA, as part of NNI, is addressing data-gaps through applied research (animal model, sentinel organs, toxicity data).
NanoCore: core facilities at NCTR, ORA/ARL to provide FDA investigators with tools to characterize and detect nanomaterials in toxicity studies and in FDA-regulated products.
Acknowledgements
NCTR/ORA Nanotechnology Core Facility:S Linder, B Miller, T Mudalige, Y Jones
Gopee et al. (FDA/NCTR; Rice Univ.; National Toxicology Program)N Gopee, D Roberts, P Webb, C Cozart, P Siitonen, J Latendresse, A Warbritton, W Yu, V Colvin, N Walker, P Howard
Sadrieh et al. (FDA/NCTR; FDA/CDER; NCI/NCL)N Sadrieh, A Wokovich, N Gopee, J Zheng, D Haines, D Parmiter, P Siitonen, C Cozart, A Patri, S McNeil, P Howard, W Doub, L Buhse